![](https://themiamientrepreneur.com/wp-content/uploads/2024/02/im-771567-rKnPvI.jpeg)
CymaBay’s stock surges as Gilead reaches $4.3 billion deal for liver-drug developer
Read Time:6 Second
CymaBay Therapeutics shares jumped 24% early Monday after Gilead Sciences reached a $4.3 billion deal to acquire the liver-drug developer.